MELA Sciences Inc  

(Public, NASDAQ:MELA)   Watch this stock  
Find more results for MELA
-0.03 (-2.56%)
Real-time:   12:51PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.14 - 1.17
52 week 1.03 - 4.05
Open 1.14
Vol / Avg. 23,487.00/50,434.00
Mkt cap 11.27M
P/E     -
Div/yield     -
EPS -3.63
Shares 9.89M
Beta 0.31
Inst. own 23%
Nov 10, 2015
Q3 2015 MELA Sciences Inc Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Sep 30, 2015
MELA Sciences Inc Annual Shareholders Meeting
Aug 13, 2015
Q2 2015 MELA Sciences Inc Earnings Call - Webcast
Aug 13, 2015
Q2 2015 MELA Sciences Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '15) 2014
Net profit margin -1284.29% -1545.90%
Operating margin -1473.81% -2190.38%
EBITD margin - -1620.98%
Return on average assets -89.12% -82.71%
Return on average equity -180.92% -155.87%
Employees 32 -
CDP Score - -


100 Lakeside Dr Ste 100
HORSHAM, PA 19044-2352
United States - Map
+1-215-6193200 (Phone)
+1-914-5913785 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


MELA Sciences, Inc. is a medical device company engaged in designing and developing software-driven technology for the early detection of skin cancer. The Company is focused on the commercialization of its product, the MelaFind System (MelaFind), as well as the further design and development of this technology. MelaFind is a non-invasive, point-of-care (in the doctor's office) instrument to aid in the detection of melanoma. The System features a hand-held component that emits light of multiple wavelengths to capture digital data from clinically atypical pigmented skin lesions. The data are then analyzed utilizing sophisticated algorithms, trained by the Company's database of melanomas and benign lesions. This result provides information to assist in the management of the patient's disease, including information useful in the dermatologist's decision on whether to biopsy the lesion.

Officers and directors

Jeffrey F. O'Donnell Sr. Chairman of the Board
Age: 55
Bio & Compensation  - Reuters
Michael R. Stewart President, Chief Executive Officer, Director
Age: 57
Bio & Compensation  - Reuters
Robert W. Cook Principal Financial Officer, Treasurer, Secretary
Age: 59
Bio & Compensation  - Reuters
David K. Stone Director
Age: 58
Bio & Compensation  - Reuters
Kathryn B. Swintek Director
Age: 62
Bio & Compensation  - Reuters
LuAnn Via Director
Age: 61
Bio & Compensation  - Reuters
Samuel E. Navarro Independent Director
Age: 59
Bio & Compensation  - Reuters